This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Treatment of RSV

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Treatment is largely symptomatic.

Main aim of management is to maintain hydration and oxygenation (1).

  • dehydration in children with bronchiolitis may occur secondary to increased respiratory rate, fever, and poor feeding caused by difficulty breathing and nasal secretions.
    • IV fluids should be considered in infants with severe respiratory difficulty, a respiratory rate greater than 80 breaths per minute, or those who visibly tire during feeding
  • intubation and ventilatory assistance are given if there is severe hypoxia
  • humidified oxygen may be required if arterial oxygen tension is low.
    • should be used in children with saturations below 90 %

A single trial of a bronchodilator may be useful in children with wheezing but routine use is not recommended (1).

Corticosteroids (oral and inhaled) may be useful in older children with a history of asthma (1).

Ribavarin, a nucleoside analogue which is active in vitro against RSV, has been shown to relieve lower respiratory tract illness in children.

  • it is used by inhalation since oral administration is associated with liver and bone marrow toxicity
  • not recommended for routine use, reserved for immunosuppressed children with severe RSV infection (1)
  • studies have yet to be conducted in adults

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.